Metabolic Interactions of Depression and Diabetes

Depression and diabetes represent two of the most burdensome chronic conditions worldwide, sharing common metabolic pathways that contribute to their frequent co-occurrence. Insulin resistance, a hallmark of type 2 diabetes, also manifests in the central nervous system of depressed individuals, disrupting neurogenesis, synaptic plasticity and reward processing. Dysregulated hypothalamic–pituitary–adrenal (HPA) axis activity links stress-mediated cortisol excess to impaired glucose homeostasis and mood disturbances. Meanwhile, low-grade systemic inflammation and oxidative stress provoke neuronal damage and exacerbate both hyperglycaemia and depressive symptoms. Key metabolic hormones such as glucagon-like peptide 1 (GLP-1) and adipokines influence brain function through modulation of appetite, energy balance and neurotransmitter release. Nutritional deficiencies—particularly in omega-3 fatty acids, B vitamins and vitamin D—further compromise both glycaemic control and mental well-being. Conversely, lifestyle interventions that improve insulin sensitivity often yield parallel benefits for mood and cognitive performance. The bidirectional interplay of metabolic dysfunction and neuropsychiatric pathology underlines the necessity of integrated clinical strategies. Recognition of these shared mechanisms has catalysed novel therapeutic approaches, ranging from antidiabetic agents with central nervous system activity to tailored dietary and behavioural programmes. Addressing the metabolic dimensions of depression may therefore not only ameliorate glycaemic outcomes but also reduce the personal and societal burden of mood disorders.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Metabolic Interactions of Depression and Diabetes publication trend

The graph below shows the total number of articles in metabolic interactions of depression and diabetes across all publications each year (not limited to Nature Index journals).

Technical terms

Insulin resistance: A state in which cells in muscle, fat and liver respond poorly to insulin, leading to impaired glucose uptake and compensatory hyperinsulinaemia.

AMP-activated protein kinase (AMPK): A cellular energy sensor that regulates glucose uptake, lipid metabolism and mitochondrial biogenesis; its activation in the brain influences mood and stress resilience.

Glucagon-like peptide 1 (GLP-1): An incretin hormone that enhances insulin secretion and suppresses appetite; it also modulates neuroinflammation and synaptic function in the central nervous system.

HPA axis: The hypothalamic–pituitary–adrenal axis, a central stress response system that controls cortisol release and influences both metabolic and emotional homeostasis.

References

1. Insulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes. Frontiers in Psychiatry (2019).
2. Antidiabetic Drug Metformin Ameliorates Depressive-Like Behavior in Mice with Chronic Restraint Stress via Activation of AMP-Activated Protein Kinase. Aging and Disease (2020).
3. Key Nutrients for Optimal Blood Glucose Control and Mental Health in Individuals with Diabetes: A Review of the Evidence. Nutrients (2023).
4. Relationship of Oxidative Stress as a Link between Diabetes Mellitus and Major Depressive Disorder. Oxidative Medicine and Cellular Longevity (2019).
5. Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. Frontiers in Pharmacology (2020).